Table of Contents

• Trial overview
• Studies in skin lupus
• Studies in systemic lupus
• What the trials measure
• Who can participate
• Trial phases and design

Trial overview

The available studies of Litifilimab are testing it in people with lupus, mainly cutaneous lupus erythematosus and systemic lupus erythematosus.^{[1][2][3][4][5]} These are interventional studies, which means researchers assign study treatment and compare results across groups.^{[1][2][3][4][5]}

All listed trials are authorised and include adults with active disease.^{[1][2][3][4][5]} Some studies compare Litifilimab with placebo, which is a look-alike treatment with no active medicine.^[1][3][4][5]

Studies in skin lupus

One major study, NCT05531565, is a Phase 4 trial in people with active subacute cutaneous lupus erythematosus and/or chronic cutaneous lupus erythematosus, with or without systemic manifestations, who are refractory or intolerant to antimalarial therapy.^[1] Refractory means the disease did not respond well to prior treatment, and intolerant means the person could not take the treatment because of side effects or other problems.^[1]

The primary goal in this skin lupus study is to see whether Litifilimab improves skin disease activity compared with placebo.^[1] In the US parts of the study, the main skin measure is the CLA-IGA-R erythema score, which tracks redness and overall skin activity.^[1] In the rest-of-world part, the study uses CLASI-70, which means at least a 70% drop in the skin activity score from the start of the study.^[1]

The long-term extension study, 2023-504863-17-00, follows adults who completed the parent skin lupus study and looks mainly at long-term safety and tolerability up to 128 weeks.^[2] This study helps researchers learn what happens with continued treatment over a longer period.^[2]

Studies in systemic lupus

Three Phase 3 studies focus on active systemic lupus erythematosus, also called SLE.^[3][4][5] These studies include adults with active SLE, and some participants receive background nonbiologic lupus standard of care, meaning their usual lupus treatment that is not a biologic medicine.^[4][5]

NCT05352919 is designed to evaluate the continuous safety and efficacy of Litifilimab in adults with active SLE, and it also includes a substudy on the safety of the device used to give the injections.^[3] The main safety outcomes are treatment-emergent adverse events and serious adverse events.^[3]

NCT04895241 and NCT04961567 both compare BIIB059, named as Litifilimab in the trial data, with placebo in adults with active SLE receiving background standard care.^[4][5] These trials are designed to show whether the treatment lowers disease activity better than placebo.^[4][5]

What the trials measure

The trials measure both efficacy, which means how well the treatment works, and safety, which means how often health problems happen during the study.^{[1][2][3][4][5]}

For skin lupus, the studies use skin-focused scores such as CLA-IGA-R and CLASI-A to see whether redness and skin activity improve.^[1] For systemic lupus, the studies use the SLE Responder Index of 4 (SRI-4) at Week 52, which is a combined way to measure whether lupus has improved enough to count as a response.^[4][5]

Safety outcomes include treatment-emergent adverse events and serious adverse events.^[2][3] A treatment-emergent adverse event is a health problem that starts or gets worse after treatment begins, while a serious adverse event is a more severe medical problem.^[2][3]

Who can participate

The skin lupus studies include adults with active subacute or chronic cutaneous lupus, with or without systemic manifestations.^[1][2] Some of these participants must also be refractory or intolerant to antimalarial therapy.^[1][2]

The systemic lupus studies include adults with active SLE, and some are receiving background lupus standard of care at the time they enter the study.^[3][4][5] The trial data do not give more detailed entry rules, so the exact eligibility requirements would need to be checked in each study record.^{[1][2][3][4][5]}

Trial phases and design

Most of the Litifilimab studies listed here are Phase 3 trials, which are usually large studies that test whether a treatment works and continues to be safe.^[2][3][4][5] One skin lupus study is a Phase 4 trial, which looks at treatment results after earlier testing has already been done.^[1]

The enrollment numbers are relatively large, ranging from 323 participants in the long-term skin lupus extension study to 948 participants in one systemic lupus trial.^[2][3] This suggests that the researchers want enough participants to compare groups and track both benefit and safety over time.^{[1][2][3][4][5]}